세계의 심근염 치료 시장 규모 조사 : 약제 클래스별, 투여 경로별, 적응증 유형별, 유통 채널별, 지역별 예측(2022-2032년)

The Global Myocarditis Treatment Market is valued at approximately USD 1.5 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.6% over the forecast period 2024-2032. Myocarditis, characterized by inflammation of the heart muscle, is commonly triggered by viral infections or autoimmune diseases. This condition compromises the heart's efficiency in pumping blood, potentially leading to severe complications such as myocardial infarction, heart failure, stroke, and arrhythmias. Prompt diagnosis and effective treatment are crucial in mitigating long-term cardiac damage. Consequently, there is a substantial emphasis on advanced treatment options that alleviate congestion during heart failure.

The burgeoning number of myocarditis cases significantly propels the growth of the myocarditis treatment market. This inflammation, primarily induced by autoimmune responses, weakens the heart's ability to pump blood efficiently. Acute myocarditis inflicts permanent damage to the heart muscle, causing severe cardiovascular events. The adoption of advanced medical infrastructure accelerates the early detection of myocarditis. Additionally, increasing awareness about early diagnosis, expanding drug pipelines, and advancements in therapeutic methodologies are pivotal drivers of market expansion. For instance, Pharmaceutical Technology reported in December 2023 that numerous companies, including Swedish Orphan Biovitrum, Bristol-Myers Squibb, and Cantargia, are developing 10 myocarditis drugs. Moreover, the National Center for Biotechnology Information (NCBI) highlighted in November 2023 that approximately 1.5 million myocarditis cases are reported globally each year, underscoring the condition's prevalence and the urgent need for effective treatments.

Regionally, North America dominated the myocarditis treatment market in 2023, driven by numerous clinical trials aimed at introducing innovative products. For example, Cardiol Therapeutics received U.S. FDA authorization in May 2022 for a multi-center Phase II study of CardiolRx targeting acute myocarditis and recurrent pericarditis. Meanwhile, the Asia Pacific region is poised for significant growth during the forecast period, owing to the increasing prevalence of cardiovascular diseases and rising public awareness about early myocarditis diagnosis.

Major market players included in this report are:

• F. Hoffmann-La Roche AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GSK plc
• Novartis AG
• Johnson & Johnson
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Inotropic Agents
• Beta-Adrenergic
• Diuretics
• Corticosteroids
• Others (Angiotensin-converting Enzyme (ACE) Inhibitors, etc.)

By Route of Administration:

• Oral
• Intravenous

By Indication Type:

• Acute Myocarditis
• Chronic Myocarditis
• Lymphocytic Myocarditis

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific:

• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America:

• Brazil
• Mexico
• RoLA

Middle East & Africa:

• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Myocarditis Treatment Market Executive Summary

• 1.1. Global Myocarditis Treatment Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Class
  • 1.3.2. By Route of Administration
  • 1.3.3. By Indication Type
  • 1.3.4. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Myocarditis Treatment Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Myocarditis Treatment Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rise in Myocarditis Cases
  • 3.1.2. Advancements in Therapeutic Methods
  • 3.1.3. Increasing Drug Pipelines
• 3.2. Market Challenges
  • 3.2.1. Complexity of Myocarditis Treatment
  • 3.2.2. High Costs Associated with Treatments
• 3.3. Market Opportunities
  • 3.3.1. Technological Advancements in Early Detection
  • 3.3.2. Expansion in Emerging Markets
  • 3.3.3. Increased Focus on Research and Development

Chapter 4. Global Myocarditis Treatment Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Myocarditis Treatment Market Size & Forecasts by Drug Class 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Myocarditis Treatment Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Inotropic Agents
  • 5.2.2. Beta-Adrenergic
  • 5.2.3. Diuretics
  • 5.2.4. Corticosteroids
  • 5.2.5. Others

Chapter 6. Global Myocarditis Treatment Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Myocarditis Treatment Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Oral
  • 6.2.2. Intravenous

Chapter 7. Global Myocarditis Treatment Market Size & Forecasts by Indication Type 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Myocarditis Treatment Market: Indication Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Acute Myocarditis
  • 7.2.2. Chronic Myocarditis
  • 7.2.3. Lymphocytic Myocarditis

Chapter 8. Global Myocarditis Treatment Market Size & Forecasts by Distribution Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Myocarditis Treatment Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies

Chapter 9. Global Myocarditis Treatment Market Size & Forecasts by Region 2022-2032

• 9.1. North America Myocarditis Treatment Market
  • 9.1.1. U.S. Myocarditis Treatment Market
    • 9.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Myocarditis Treatment Market
• 9.2. Europe Myocarditis Treatment Market
  • 9.2.1. U.K. Myocarditis Treatment Market
  • 9.2.2. Germany Myocarditis Treatment Market
  • 9.2.3. France Myocarditis Treatment Market
  • 9.2.4. Spain Myocarditis Treatment Market
  • 9.2.5. Italy Myocarditis Treatment Market
  • 9.2.6. Rest of Europe Myocarditis Treatment Market
• 9.3. Asia-Pacific Myocarditis Treatment Market
  • 9.3.1. China Myocarditis Treatment Market
  • 9.3.2. India Myocarditis Treatment Market
  • 9.3.3. Japan Myocarditis Treatment Market
  • 9.3.4. Australia Myocarditis Treatment Market
  • 9.3.5. South Korea Myocarditis Treatment Market
  • 9.3.6. Rest of Asia Pacific Myocarditis Treatment Market
• 9.4. Latin America Myocarditis Treatment Market
  • 9.4.1. Brazil Myocarditis Treatment Market
  • 9.4.2. Mexico Myocarditis Treatment Market
  • 9.4.3. Rest of Latin America Myocarditis Treatment Market
• 9.5. Middle East & Africa Myocarditis Treatment Market
  • 9.5.1. Saudi Arabia Myocarditis Treatment Market
  • 9.5.2. South Africa Myocarditis Treatment Market
  • 9.5.3. Rest of Middle East & Africa Myocarditis Treatment Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. F. Hoffmann-La Roche AG
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Mylan N.V.
  • 10.3.3. Teva Pharmaceutical Industries Ltd.
  • 10.3.4. Pfizer Inc.
  • 10.3.5. GSK plc
  • 10.3.6. Novartis AG
  • 10.3.7. Johnson & Johnson
  • 10.3.8. Bayer AG
  • 10.3.9. Sun Pharmaceutical Industries Ltd.
  • 10.3.10. Merck & Co., Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes